Early effects of human papillomavirus vaccination in Belgium

被引：11

作者：

Merckx, Mireille ^{[1
,2
]}

Vanden Broeck, Davy ^{[1
]}

Benoy, Ina ^{[3
]}

Depuydt, Christophe ^{[3
]}

Weyers, Steven ^{[2
]}

Arbyn, Marc ^{[4
]}

机构：

[1] Univ Ghent, ICRH, B-9000 Ghent, Belgium

[2] Ghent Univ Hosp, Dept Obstet & Gynaecol, Ghent, Belgium

[3] Son Hlth Care AML, Antwerp, Belgium

[4] Sci Inst Publ Hlth, Canc Epidemiol Unit, Brussels, Belgium

来源：

EUROPEAN JOURNAL OF CANCER PREVENTION | 2015年 / 24卷 / 04期

关键词：

CROSS-PROTECTIVE EFFICACY; GRADE CERVICAL LESIONS; METAANALYSIS; PREVENTION; INFECTION; CANCER;

D O I：

10.1097/CEJ.0000000000000067

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Human papillomavirus (HPV) vaccination has been reimbursed in Belgium since 2007 for girls (12-15 years), extended to girls up to 18 years in 2008. This study assesses the trend of HPV 16/18 infections in women less than 25 years of age participating in opportunistic cervical cancer screening. A significant reduction in the prevalence of HPV 16 [relative risk (RR)=0.61, 95% confidence interval=0.39-0.95] and a nonsignificant reduction in HPV 18 (RR=0.65, 95% confidence interval=0.29-1.48) was found in the youngest group (15-19 years). The prevalences in the older age group did not change significantly. These findings show the early effects of HPV vaccination and confirm the effectiveness of immunization in a real-life setting.

引用

页码：340 / 342

页数：3

共 15 条

[1] Cervical cancer screening in Belgium [J].

Arbyn, M ;

Van Oyen, H .

EUROPEAN JOURNAL OF CANCER, 2000, 36 (17) :2191-2197

[2] Introduction of Human Papillomavirus Vaccination in Belgium, Luxembourg and the Netherlands [J].

Arbyn, M. ;

Simoens, C. ;

Van Damme, P. ;

Scharpantgen, A. ;

Meijer, C. J. L. M. ;

Beutels, P. .

GYNECOLOGIC AND OBSTETRIC INVESTIGATION, 2010, 70 (04) :224-232

[3] EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease [J].

Arbyn, Marc ;

de Sanjose, Silvia ;

Saraiya, Mona ;

Sideri, Mario ;

Palefsky, Joel ;

Lacey, Charles ;

Gillison, Maura ;

Bruni, Laia ;

Ronco, Guglielmo ;

Wentzensen, Nicolas ;

Brotherton, Julia ;

Qiao, You-Lin ;

Denny, Lynnette ;

Bornstein, Jacob ;

Abramowitz, Laurent ;

Giuliano, Anna ;

Tommasino, Massimo ;

Monsonego, Joseph .

INTERNATIONAL JOURNAL OF CANCER, 2012, 131 (09) :1969-1982

[4] Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis [J].

Clifford, GM ;

Smith, JS ;

Aguado, T ;

Franceschi, S .

BRITISH JOURNAL OF CANCER, 2003, 89 (01) :101-105

[5] Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis [J].

Malagon, Talia ;

Drolet, Melanie ;

Boily, Marie-Claude ;

Franco, Eduardo L. ;

Jit, Mark ;

Brisson, Jacques ;

Brisson, Marc .

LANCET INFECTIOUS DISEASES, 2012, 12 (10) :781-789

[6]

Micalessi IM, 2012, CLIN CHEM LAB MED, V50, P655, DOI [10.1515/CCLM.2011.835, 10.1515/cclm.2011.835]

[7] GENERALIZED LINEAR MODELS [J].

NELDER, JA ;

WEDDERBURN, RW .

JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES A-GENERAL, 1972, 135 (03) :370-+

[8] Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women [J].

Paovonen, J. ;

Naud, P. ;

Salmeron, J. ;

Wheeler, C. M. ;

Chow, S-N ;

Apter, D. ;

Kitchener, H. ;

Castellsague, X. ;

Teixeira, J. C. ;

Skinner, S. R. ;

Hedrick, J. ;

Jaisamrarn, U. ;

Limson, G. ;

Garland, S. ;

Szarewski, A. ;

Romanowski, B. ;

Aoki, F. Y. ;

Schwarz, T. F. ;

Poppe, W. A. J. ;

Bosch, F. X. ;

Jenkins, D. ;

Hardt, K. ;

Zahaf, T. ;

Descamps, D. ;

Struyf, F. ;

Lehtinen, M. ;

Dubin, G. .

LANCET, 2009, 374 (9686) :301-314

[9] Cervical adenocarcinoma: Moving towards better prevention [J].

Seoud, Muhieddine ;

Tjalma, Wiebren A. A. ;

Ronsse, Veerle .

VACCINE, 2011, 29 (49) :9148-9158

[10]

Simoens C, 2009, EUROSURVEILLANCE, V14, P1

← 1 2 →